Current Cardiology Reviews最新文献_第9页

Current Cardiology Reviews Pub Date : 2023-11-01 DOI: 10.2174/1573403x1906231002102918

引用次数: 0

Prevention of Contrast-induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention. 经皮冠状动脉介入治疗患者造影剂肾病的预防。

IF 2.4

Current Cardiology Reviews Pub Date : 2023-10-24 DOI: 10.2174/011573403X260319231016075216

Raymond Pranata, Dendi Puji Wahyudi

{"title":"Prevention of Contrast-induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention.","authors":"Raymond Pranata, Dendi Puji Wahyudi","doi":"10.2174/011573403X260319231016075216","DOIUrl":"10.2174/011573403X260319231016075216","url":null,"abstract":"Contrast-induced nephropathy (CIN) or contrast-induced acute kidney injury has varying definitions, but in general, increased serum creatinine level by ≥ 0.3 mg/dL (26.5 µmol/L) or 1.5x of baseline value or urine output <0.5 mL/kg/h within 1-7 days after contrast media (CM) administration can be considered as CIN. CIN is one of the most common complications and is associated with increased mortality in patients undergoing percutaneous coronary intervention (PCI). Thus, risk stratification for CIN should be made and preventive strategies should be employed in which the intensity of the approach must be tailored to patient's risk profile. In all patients, adequate hydration is required, nephrotoxic medications should be discontinued, and pre-procedural high-intensity statin is recommended. In patients with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, IV hydration should be started 12 hours pre-procedure up until 12-24 hours after the procedure. Remote ischemic preconditioning may be performed pre-procedurally. Radial first approach for vascular access is recommended. During the procedure, low or iso-osmolar CM should be used and its volume should be limited to eGFR x 3.7. In patients at high risk for CIN, additional contrast-sparing strategies may be applied, such as using a contrast reduction system, 5 Fr catheter with no sideholes, CM dilution, limiting test injection, confirming placement using guidewire, use of stent enhancing imaging technology, using metallic/software roadmap to guide PCI, use of IVUS or dextran-based OCT, and coronary aspiration. A more advanced hydration technique based on central venous pressure, left ventricular end-diastolic pressure, or using furosemide-matched hydration, might be considered.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50157263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When Pulmonary Arterial Hypertension may be Associated with Portal Hypertension: A Case Report of Two Different Hepatic Disorders in One Patient with Pulmonary Hypertension. 肺动脉高压何时可能与门静脉高压相关：一例肺动脉高压患者两种不同肝脏疾病的病例报告。

IF 2.4

Current Cardiology Reviews Pub Date : 2023-10-20 DOI: 10.2174/011573403X267162231011154808

Ganna Radchenko, Yuriy Sirenko

{"title":"When Pulmonary Arterial Hypertension may be Associated with Portal Hypertension: A Case Report of Two Different Hepatic Disorders in One Patient with Pulmonary Hypertension.","authors":"Ganna Radchenko, Yuriy Sirenko","doi":"10.2174/011573403X267162231011154808","DOIUrl":"10.2174/011573403X267162231011154808","url":null,"abstract":"Background: pulmonary arterial hypertension (PAH) is a rare complication of hepatic diseases with portal hypertension that, however, has a significant influence on prognosis. We present a mini-review of how to diagnose and treat it based on a clinical case.Case presentation: in early childhood, a patient had portal hypertension associated with cavernous transformation of the portal vein. It was successfully treated by reno-splenic surgery. At the age of 20 years, this patient experienced increased dyspnea at minimal physical activity after the hepatic biopsy due to a hepatocellular adenoma. The examination in the specialized unit showed PAH, which was evaluated as associated with portal hypertension (PAH-PoH). The specific two-drug combination therapy was started with prominent improvement in patient's state. Successful surgical tumor treatment was provided some months later. The practical and clinical approaches to the diagnosis and treatment of PAH-PoH are discussed. It was emphasized that not all patients with portal hypertension have pulmonary hypertension, which needs to be treated. A lot of evidence gaps exist in management of these patients.Conclusion: all patients, even with past history of portal hypertension, should be monitored closely and screened for PAH earlier, for better results of treatment.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50161042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fetal Aortic And Umbilical Doppler Flow Velocity Waveforms In Pregnancy: The Concept of Aortoumbilical Column 妊娠期胎儿主动脉和脐多普勒血流速度波形:主动脉-脐柱的概念

Current Cardiology Reviews Pub Date : 2023-10-10 DOI: 10.2174/011573403x255256230919061018

De Almeida Ana Beatriz, Morais Ana Rita, Ferreira Miguel, Gaio Ana Rita, Guedes-Martins Luís

{"title":"Fetal Aortic And Umbilical Doppler Flow Velocity Waveforms In Pregnancy: The Concept of Aortoumbilical Column","authors":"De Almeida Ana Beatriz, Morais Ana Rita, Ferreira Miguel, Gaio Ana Rita, Guedes-Martins Luís","doi":"10.2174/011573403x255256230919061018","DOIUrl":"https://doi.org/10.2174/011573403x255256230919061018","url":null,"abstract":"Abstract: Low impedance within the uteroplacental circulation is crucial for fetal development. Flow velocity waveforms (FVW) have been established for the aortic and umbilical arteries in low-risk pregnancies during the second half of pregnancy, but data regarding early gestation is limited. Both vascular territories exhibit higher impedance patterns in pregnancies complicated by fetal growth restriction (FGR), hypertensive disorders, fetal anemia, and chromosomal abnormalities. Early identification of these complications is critical in obstetric practice, to reduce perinatal morbidity and mortality through prevention and close antenatal surveillance. Available data suggest that aortic and umbilical impedances follow the same variation pattern as pregnancy progresses. This observation implies that both vessels may be considered as a single artery, referred to as the “aortoumbilical column”. Our hypothesis posits that changes in the hemodynamic pattern of this column could identify high-risk pregnancies, particularly those complicated by preeclampsia, FGR, intrauterine fetal demise, fetal aneuploidies, and fetal anemia. Understanding vascular embryogenesis and the FVWs of the aortic and umbilical arteries enables comprehension of impedance changes throughout normal pregnancies. The continuous variation in impedance along a single vessel supports our concept of the aortoumbilical column. Deviations from the regular pattern could assist in identifying compromised fetuses during early pregnancy. Further research on normal aortoumbilical column FVW and the development of reference charts is necessary to consider this arterial column as a screening tool in clinical practice.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136360130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Amyloidosis: A Contemporary Review of Medical and Surgical Therapy 心脏淀粉样变性:内科和外科治疗的当代回顾

Current Cardiology Reviews Pub Date : 2023-10-04 DOI: 10.2174/011573403x240302230925043500

Drew Brownell, Aiswarya J Pillai, Nandini Nair

{"title":"Cardiac Amyloidosis: A Contemporary Review of Medical and Surgical Therapy","authors":"Drew Brownell, Aiswarya J Pillai, Nandini Nair","doi":"10.2174/011573403x240302230925043500","DOIUrl":"https://doi.org/10.2174/011573403x240302230925043500","url":null,"abstract":"Abstract: Amyloidosis is a systemic disease initiated by deposition of misfolded proteins in the extracellular space, due to which multiple organs may be affected concomitantly. Cardiac amyloidosis, however, remains a major cause of morbidity and mortality in this population due to infiltrative /restrictive cardiomyopathy. This review attempts to focus on contemporary medical and surgical therapies for the different types of cardiac amyloidosis. Amyloidosis affecting the heart are predominantly of the transthyretin type (acquired in the older or genetic in the younger patients), and the monoclonal immunoglobulin light chain (AL) type which is solely acquired. A rare form of secondary amyloidosis AA type can also affect the heart due to excessive production and accumulation of the acute-phase protein called Serum Amyloid A” (SAA) in the setting of chronic inflammation, cancers or autoinflammatory disease. More commonly AA amyloidosis is seen in the liver and kidney. Other rare types are Apo A1 and Isolated Atrial Amyloidosis (AANF). Medical therapies have made important strides in the clinical management of the two common types of cardiac amyloidosis. Surgical therapies such as mechanical circulatory support and cardiac transplantation should be considered in appropriate patients. Future research using AI driven algorithms for early diagnosis and treatment as well as development of newer genetic engineering technologies will drive improvements in diagnosis, treatment and patient outcomes.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135647384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Valve Repair in Aortic Insufficiency: A State-of-the-art Review. 主动脉瓣关闭不全的瓣膜修复：最新进展。

IF 1.9

Current Cardiology Reviews Pub Date : 2023-01-01 DOI: 10.2174/1573403X18666220427120235

Leandros Sassis, Pelagia Kefala-Karli, Irene Cucchi, Ilias Kouremenos, Michalis Demosthenous, Konstantinos Diplaris

引用次数: 0

Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India. 印度慢性冠状动脉综合征和心力衰竭患者射血分数降低的以艾伐拉定为基础的心率管理治疗专家共识。

IF 2.4

Current Cardiology Reviews Pub Date : 2023-01-01 DOI: 10.2174/1573403X19666230320105623

J C Mohan, I Sathyamurthy, Monotosh Panja, Rajeev Agarwala, C K Ponde, A Sreenivas Kumar, Bijay Kumar Mahala, Vivek Kolapkar, R V Lokesh Kumar, Kamlesh Patel

{"title":"Expert Consensus on Ivabradine-based Therapy for Heart Rate Management in Chronic Coronary Syndrome and Heart Failure with Reduced Ejection Fraction in India.","authors":"J C Mohan, I Sathyamurthy, Monotosh Panja, Rajeev Agarwala, C K Ponde, A Sreenivas Kumar, Bijay Kumar Mahala, Vivek Kolapkar, R V Lokesh Kumar, Kamlesh Patel","doi":"10.2174/1573403X19666230320105623","DOIUrl":"10.2174/1573403X19666230320105623","url":null,"abstract":"Heart rate is an important indicator of health and disease and the modulation of heart rate can help to improve cardiovascular outcomes. Besides β-blockers, Ivabradine is a wellestablished heart rate modulating drug that reduces heart rate without any hemodynamic effects. This consensus document was developed with the help of expert opinions from cardiologists across India on effective heart rate management in routine clinical practice and choosing an appropriate Ivabradine-based therapy considering the available scientific data and guideline recommendations. Based on the discussion during the meetings, increased heart rate was recognized as a significant predictor of adverse cardiovascular outcomes among patients with chronic coronary syndromes and heart failure with reduced ejection fraction making heart rate modulation important in these subsets. Ivabradine is indicated in the management of chronic coronary syndromes and heart failure with reduced ejection fraction for patients in whom heart rate targets cannot be achieved despite guideline-directed β-blocker dosing or having contraindication/intolerance to β-blockers. A prolonged release once-daily dosage of Ivabradine can be considered in patients already stabilized on Ivabradine twice-daily. Ivabradine/β-blocker fixed-dose combination can also be considered to reduce pill burden. Two consensus algorithms have been developed for further guidance on the appropriate usage of Ivabradine-based therapies. Ivabradine and β-blockers can provide more pronounced clinical improvement in most chronic coronary syndromes and heart failure with reduced ejection fraction patients with a fixed-dose combination providing an opportunity to improve adherence.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":"19 5","pages":"97-106"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10341235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and Structural Factors Affecting Ablation Outcomes in Atrial Fibrillation Patients - A Review. 影响心房颤动患者消融结果的临床和结构因素——综述。

IF 2.4

Current Cardiology Reviews Pub Date : 2023-01-01 DOI: 10.2174/1573403X19666230331103153

Justin Brilliant, Ritu Yadav, Tauseef Akhtar, Hugh Calkins, Natalia Trayanova, David Spragg

引用次数: 0

First Trimester Tricuspid Regurgitation: Clinical Significance. 第一个三尖瓣返流：临床意义。

IF 1.9

Current Cardiology Reviews Pub Date : 2023-01-01 DOI: 10.2174/1573403X19666221206115642

Sofia Teixeira, Luís Guedes-Martins

引用次数: 0

Heart Failure And Type 2 Diabetes Mellitus: Neurohumoral, Histological And Molecular Interconnections. 心力衰竭与2型糖尿病：神经体液、组织学和分子相互作用。

IF 1.9

Current Cardiology Reviews Pub Date : 2023-01-01 DOI: 10.2174/1573403X18666220617121144

A Ushakov, V Ivanchenko, A Gagarina

引用次数: 0